Samsung Life Science Fund, created jointly between Samsung Biologics, Samsung Bioepis, and Samsung C&T, and managed by Samsung Ventures, announced its investment in BrickBio, a preclinical-stage biopharmaceutical company focused on developing antibody-drug conjugate (ADC) drugs.The latest investment
CHA Biotech said Monday that it has signed a contract development and manufacturing organization (CDMO) agreement with Cell in Cells, a regenerative medicine cell therapies developer, to provide organoid treatment for cartilage diseases.Under the agreement, CHA Biotech will establish a cell bank of
Celltrion officially launched Zymfentra, also known as Remsima SC in Europe, in the U.S., last Friday.Zymfentra is the world's only subcutaneous (SC) form of infliximab, having received FDA approval in October of the previous year. Under the approval, the drug can treat moderate to severe active ulc
NeoImmuneTech said Friday that its board of directors has decided to establish a Polish subsidiary to prepare for full-scale clinical trials in the European market.NeoImmuneTech expects that the Polish subsidiary's possible designation as a European small and medium enterprise (SME) will enable it t
In a move reflecting the intricate dance between branding, legal challenges, and market positioning, two Korean biotech companies, LegoChem Biosciences and Helixmith, have announced changes to their corporate identities.LegoChem Biosciences will soon undergo a transformation to LigaChem Biosciences,
NGeneBio, a company specializing in next-generation sequencing-based precision diagnostic platforms, said Wednesday that it has signed a business agreement with Genolution, a molecular diagnostics company."We signed this business agreement to provide NGS (next-generation sequencing) testing services
Celltrion said it has completed its application to the U.S. FDA for the approval of CT-P39, a biosimilar referencing Xolair (ingredient: omalizumab). Xolair was developed by Genentech and Novartis for the treatment of allergic asthma, chronic rhinosinusitis with nasal polyposis, and chronic idiopath
Shaperon, a Korean biotech company, said Thursday that it has completed enrollment of the first patient in its U.S. phase 2 clinical trial of NuGel for treating atopic dermatitis.The trial is designed to evaluate NuGel in 210 patients of various ethnicities with mild to moderate atopic dermatitis fo
Samsung Biologics said Tuesday that it has signed a contract manufacturing agreement worth 381.9 billion won ($352.79 million, based on USD/KRW 1,082.90 on Dec. 21, 2017) with Belgium-based UCB. The contract is an extension of a $41.65 million contract signed with the Belgian company in 2017.UCB is
Curocell, a Kosdaq-listed biotech company, said it received the topline data from its phase 2 clinical trial for its CAR-T (chimeric antigen receptor-T) therapy, Anbal-cel, to treat diffuse large B-cell lymphoma (DLBCL).The study is Korea's first clinical trial of a CAR-T therapy, involving 79 adult
Osang Healthcare said it recorded a 2,126 to 1 competition ratio in the company’s public share subscription for retail investors on Monday and Tuesday. The subscription deposit amounted to about 5.26 trillion won ($39.3 billion).Osang Healthcare's five-day demand forecast from Feb. 21 to 27 attracte
Bridge Biotherapeutics has reported a significant downturn in its financial performance for the year 2023.The company's annual revenue plummeted to 100 million won ($74,878), marking a drastic 96.7 percent decrease compared to the previous year.This downturn is attributed to the absence of additiona
Cosmetic device maker ilooda said Monday that it had signed a settlement agreement with Serendia LLC to resolve a U.S. International Trade Commission (ITC) investigation.In March 2023, Serendia filed a complaint with the ITC, alleging ilooda’s infringement on its "invasive RF" patent.Invasive RF is
Celltrion said it reported consolidated sales of 2.1 trillion won ($1.5 billion) and operating income of 651 billion won in 2023, down 4.71 percent and up 0.66 percent, respectively, from the previous year.The company also posted a net profit of 539.2 billion won, down 0.53 percent, and an operating
CHA Biotech said it had achieved its highest-ever annual revenue, posting a consolidated revenue of 954 billion won ($798 million) for the year 2023, up 13 percent from the previous year, thanks to strong business performance overseas.Despite the global economic slowdown, CHA Biotech attributed its
NGeneBio, a precision diagnostics platform company, has received approval from the Thai Food and Drug Administration (TFDA) to market HLAaccuTest™ All, an in vitro diagnostic medical device based on next-generation sequencing (NGS) technology.It is the fourth NGS-based product approved for registrat
Biotech companies developing new drugs are plagued by rumors that adversely affect investor sentiment.Faced with a series of speculations about the equity sale by the largest shareholders and plans for a capital increase, SCM Lifescience, ABL Bio, NKMAX, and Genome & Company have responded with offi
Celltrion said it has commenced the first shipment of Zymfentra, the world’s first subcutaneous form of infliximab, to the U.S. targeting autoimmune diseases. The company announced that the initial shipment batch was airlifted today to Atlanta, U.S., with plans to complete three shipment phases by e
CHA Biotech has launched a study to enhance the anticancer efficacy of its natural killer (NK) cell therapeutic drug by making the most of polymer, a cationic compound.The cationic compounds used in the study are synthetic polymers, in which monomers, molecules with low molecular weight, are repeate
Pharos iBio will collaborate with the team of Professor Shin Sang-joon of the Department of Medical Oncology at Yonsei Cancer Center to conduct the translational study of PHI-501 under development for treating solid tumors.PHI-501 is a pipeline of solid tumor therapeutics in preclinical development.